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Abstract
Introduction: Stimulant and heavy alcohol use are prevalent and associated with elevated risk for HIV seroconversion among
men who have sex with men (MSM) and transgender women. In addition, each can pose difficulties for antiretroviral adherence
among people living with HIV. Scant research has examined the associations of stimulant and heavy alcohol use with adher-
ence to daily oral pre-exposure prophylaxis (PrEP) among MSM and transgender women. To address this gap in the literature,
we evaluated the hypothesis that stimulant use and binge drinking are prospectively associated with sub-optimal PrEP adher-
ence.
Methods: We analysed data from participants in a nested case-cohort in the iPrEx open label extension. Stimulant use (i.e.
powder cocaine, crack-cocaine, cocaine paste, methamphetamine, cathinone) and binge drinking (i.e. ≥5 drinks in a single day)
in the last 30 days were assessed. Baseline urine was tested for stimulants using immunoassays to reduce misclassification.
Sub-optimal adherence was defined as tenofovir drug concentrations in dried blood spots less than 700 fmol per punch,
indicative of less than four doses per week. We tested the prospective association of stimulant use and binge drinking with
sub-optimal adherence at the 4-week follow-up visit.
Results and Discussion: Data from 330 participants were analysed. The majority of the participants were MSM (89%) with a
median age at baseline of 29 years (interquartile range 24 to 39). Approximately 16% (52/330) used stimulants and 22% (72/
330) reported binge drinking in the last 30 days. Stimulant users had fivefold greater odds of sub-optimal PrEP adherence
compared to non-users in adjusted analysis (adjusted odds ratio [aOR] 5.04; [95% CI 1.35 to 18.78]). Self-reported binge
drinking was not significantly associated with sub-optimal adherence after adjusting for stimulant use and baseline confounders
(aOR 1.16 [0.49 to 2.73]). Depressive symptoms, being transgender, and number of sex partners were also not significantly
associated with sub-optimal PrEP adherence (p > 0.05).
Conclusions: Stimulant use is a risk factor for sub-optimal PrEP adherence in the month following PrEP initiation. Comprehen-
sive prevention approaches that reduce stimulant use may optimize PrEP adherence. Creating adherence plans that specifically
address PrEP dosing in the context of ongoing stimulant use should also be considered.
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1 | INTRODUCTION
Men who have sex with men (MSM) are 24 times more likely
to become infected with HIV compared to the general popula-
tion, while transgender women are nearly 50 times more likely
to become infected [1]. Daily oral HIV pre-exposure prophy-
laxis (PrEP) using emtricitabine-tenofovir disoproxyl fumarate
(FTC-TDF) has demonstrated efficacy in preventing HIV infec-
tion [2-6] and is a promising strategy for these key popula-
tions. In the iPrEx trial [2], MSM and transgender women
taking PrEP had an overall 44% reduction in HIV acquisition.
More recent data from the PROUD study [6] reported a
relative reduction of 86% among individuals taking daily oral
PrEP, suggesting that this strategy is highly effective in pre-
venting HIV in high priority populations.
However, the unprecedented clinical and public health bene-
fits of PrEP require sustained, prevention effective levels of
adherence during periods of exposure to HIV [3,7]. In the
iPrEx Open Label Extension (OLE), drug concentrations in
dried blood spots (DBS) corresponding to four or more doses
of FTC-TDF per week (i.e. ≥700 fmol per punch) were associ-
ated with no new HIV infections [3]. But despite high interest
and uptake of PrEP among MSM and transgender women
[8,9], a considerable proportion of individuals either
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discontinue or struggle to adhere to the regimen shortly after
initiation [3,10]. In several studies, all acute HIV seroconver-
sions occurred exclusively during periods of inadequate PrEP
adherence or when PrEP was discontinued [3,4,7].
Existing studies have not clearly elucidated the reasons for
sub-optimal PrEP adherence among MSM and transgender
women [11], but alcohol and stimulant use may be important
risk factors. Stimulant and heavy alcohol use are well-estab-
lished correlates of HIV acquisition and poor treatment out-
comes among HIV-positive individuals [12,13]. There is also
increasing recognition that “chemsex,” or the use of a combina-
tion of sex enhancing drugs like stimulants, has become increas-
ingly common among MSM residing in industrialized nations
[14,15]. In a large observational study of MSM, stimulant use
was independently associated with a threefold increase in risk
for HIV seroconversion and an eightfold increase when com-
bined with other chemsex drugs such as poppers [16]. In the
United States, estimates of stimulant use range between 6%
and 17% among MSM [17] and between 21% and 26% among
transgender women [18-20]. Reports also suggest high rates of
alcohol use in these individuals (approximately 56% in MSM and
44% in transgender women) [17,19]. However, the associations
of stimulant use and heavy alcohol use with sub-optimal PrEP
adherence is not well understood. To address this gap in knowl-
edge, this study evaluated the hypothesis that stimulant use
and binge drinking at baseline are prospectively associated with
early sub-optimal PrEP adherence in an observational cohort of
MSM and transgender women.
2 | METHODS
2.1 | Study participants
We analysed data from participants in a nested case-cohort in
iPrEx OLE. Individuals in the case-cohort had drug concentra-
tions measured at each time point after PrEP dispensation.
The parent study and the design of the case-cohort are
described in detail elsewhere [3,21]. Briefly, participants were
enrolled at 11 sites across six countries (Brazil, Ecuador, Peru,
South Africa, Thailand and the United States) between June
2011 and June 2012, and followed for up to 72 weeks. Visits
were scheduled 4, 8 and 12 weeks after enrolment, and quar-
terly thereafter. Participants were male sex at birth, reported
having anal sex with men, and were at least 18 years of age.
All participants provided informed consent as part of the par-
ent study. The iPrEx OLE study protocol was approved by
institutional review boards at each site and by relevant
national regulatory agencies. This study was approved by the
Committee on Human Research at the University of Califor-
nia, San Francisco.
2.2 | Measures
2.2.1 | Stimulant use and binge drinking
Participants reported any stimulant use and binge drinking in
the last 30 days using computer-assisted self-interview (CASI).
Stimulants included powder cocaine, crack-cocaine, cocaine
paste, methamphetamine, and the amphetamine analogue,
cathinone. Immunochemical screening of banked urine col-
lected at baseline was used to validate self-reported stimulant
use. Participants who denied any recent stimulant use but had
a positive urine immunoassay were coded as having used stim-
ulants. Binge drinking was defined as consuming ≥5 alcoholic
drinks in a single day by self-report.
2.2.2 | Depressive symptoms
Depressive symptoms at baseline were measured using the
Centre for Epidemiologic Studies Depression (CES-D) scale, a
validated 20-item measure that assesses for the frequency of
depressive symptoms in the past week [22]. Standard clinical
cut-offs were used to categorize CES-D scores: none-mild
depression (0 to 15); mild-moderate depression (16 to 26);
and severe depression (≥27).
2.2.3 | Sexual risk behaviours
Condomless sex and the number of sex partners in the last
three months were assessed at baseline using an interviewer-
administered questionnaire.
2.2.4 | Sub-optimal PrEP adherence
Participants in the case-cohort had PrEP adherence estimated
by tenofovir diphosphate (TFV-DP) concentrations in DBS, as
described previously [3]. TFV-DP concentrations <700 fmol
per punch corresponds to an average of less than four doses
per week. This dosing pattern provides sub-optimal protection
against HIV [3].
2.3 | Analysis
We tested the direct association of baseline stimulant use and
binge drinking with sub-optimal PrEP adherence at the 4-
week follow-up visit using logistic models. Probability weights
were used to account for the case-cohort design. As a sensi-
tivity analysis, we repeated our analysis using a robust vari-
ance estimator to account for clustering within site. Because
there were no observed differences in effect size estimates,
we report analyses that do not adjust for clustering given the
relatively modest number of sites in this project. We evalu-
ated PrEP adherence at the 4-week follow-up visit based on
previous analysis that demonstrated that poor adherence at
this visit was highly predictive of future adherence patterns
[23]. Relevant baseline confounders were identified using a
directed acyclic graph [24]. Each predictor was modelled indi-
vidually then as a predictor set. Covariate selection for the
final model was based on changes in statistical precision [24].
Any sexually transmitted infection at enrolment was omitted
in the final model as this resulted in a substantially larger
standard error. Given the high prevalence of depression
among MSM and transgender women [25,26] and the bivari-
ate association between depression and non-adherence
[27,28], we tested for the possible interaction between our
predictors of interest and baseline CES-D score. We also
tested for the possible interaction between stimulant use and
binge drinking. However, we found no evidence of effect
heterogeneity (p > 0.05) or any qualitatively meaningful
changes in effect size estimates, so these terms were not
included in the final model. All analyses were conducted using
Stata 14 (College Station, TX).
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3 | RESULTS
3.1 | Sample characteristics
A total of 349 participants were included in the iPrEx OLE
case-cohort. Data from 330 participants who provided consent
for long-term specimen banking and testing were included in
this analysis (Table 1). Median age at baseline was 29 years (in-
terquartile range [IQR] 24 to 39) and median number of sex
partners in the last three months was two (IQR 1 to 5). Most
identified as MSM (89%), Latino or Hispanic (57%), and had
completed at least secondary education (78%). Approximately
16% (52/330) used stimulants and 22% (72/330) reported
binge drinking in the last month. Nearly half (49%) of all partici-
pants reported engaging in any condomless sex in the previous
three months at baseline.
3.2 | PrEP adherence
TFV-DP concentrations in DBS at the 4-week follow-up were
available in 293 participants. Of those with available TFV-DP
data, approximately 47% (137/293) had drug concentrations
indicative of less than four doses in the prior week. Approxi-
mately 55% of stimulant users (24/44) and binge drinkers (34/
62) were sub-optimally adherent at the 4-week follow-up visit.
In adjusted analysis, stimulant use was significantly associ-
ated with sub-optimal PrEP adherence (Table 2). Stimulant
users were five times more likely to have TVF-DP concen-
trations <700 fmol per punch at the 4-week follow-up com-
pared to non-users (adjusted odds ratio [aOR] 5.04; [95%
CI: 1.35 to 18.78]). Binge drinking was not significantly
associated with sub-optimal adherence (aOR 1.16 [0.49 to
2.73]). Total number of partners in the last three months
and depressive symptoms were also not significantly associ-
ated with sub-optimal PrEP adherence. We found no statis-
tically significant linear trend for total number of partners
(p = 0.87) and CES-D score (p = 0.79) in the multivariable
model. When we limited our analysis to only MSM, we
observed a slightly larger association of stimulant use on
sub-optimal adherence (aOR 8.82 [2.05 to 37.90]). The
association of binge drinking remained non-significant (aOR
1.31 [0.52 to 3.34]).
4 | DISCUSSION
This study is among the first to document that stimulant use
is associated with a fivefold greater odds of sub-optimal PrEP
adherence, measured by TFV-DP drug concentrations below
Table 1. Baseline demographics and participant characteristics
(N = 330)
Median (IQR)
Age 29 (24 to 39)
Total number of partners in last 3 months 2 (1 to 5)
n (%)
Study region
Andesa 165 (50)
Brazil 68 (21)
South Africa 19 (6)
Thailand 18 (5)
United States 60 (18)
Men who have sex with men 295 (89)
Transgender women 35 (11)
Latino or Hispanic 187 (57)
Education
Less than secondary 71 (22)
Completed secondary 106 (32)
Post-secondary 152 (46)
Baseline CES-Db score
<16 237 (72)
16 to 26 63 (19)
≥27 29 (9)
Stimulant use in the last 30 daysc 52 (16)
Binge in the last 30 daysd 72 (22)
Condomless anal sex in the last 3 months 161 (49)
IQR, interquartile range.
aIncludes sites in Ecuador and Peru.
bCentre for Epidemiologic Studies Depression scale.
cStimulant use based on self-report or positive urine immunoassay.
Includes powder cocaine, crack-cocaine, cocaine paste, metham-
phetamine and cathinone (amphetamine analogue).
d≥5 alcoholic drinks in a single day.
Table 2. Baseline correlates of sub-optimal PrEP adherence at
the 4-week follow-up visit (n = 293)
Adjusted OR (95% CI) p-value
Stimulant use in the
last 30 daysa
5.04 (1.35 to 18.78) 0.02
Binge drinking in the
last 30 daysb
1.16 (0.49 to 2.73) 0.74
Transgender 1.24 (0.20 to 7.58) 0.82
Total number of partners in the last 3 months
0 to 1 partners Ref
2 to 3 partners 0.78 (0.25 to 2.40) 0.67
≥4 partners 0.91 (0.28 to 2.99) 0.87
CES-D scorec
<16 Ref
16 to 26 0.43 (0.15 to 1.18) 0.10
≥27 1.18 (0.34 to 4.11) 0.79
Multivariable model also controlled for study region, age, education,
and Latino or Hispanic ethnicity. Sub-optimal adherence is defined
as tenofovir diphosphate (TFV-DP) concentrations <700 fmol per
punch based on dried blood spots (DBS), corresponding to <4
doses per week. All predictors were assessed at the baseline visit.
We found no statistically significant linear trend for total number of
partners (p = 0.87) and CES-D score (p = 0.79) in the multivariable
model.
aStimulant use based on self-report or positive urine immunoassay.
Includes powder cocaine, crack-cocaine, cocaine paste, metham-
phetamine and cathinone (amphetamine analogue).
bBinge drinking is ≥5 alcoholic drinks in a single day.
cCentre for Epidemiologic Studies Depression (CES-D) scale.
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the established threshold to maximize protection against HIV.
The association between stimulant use and poor adherence to
antiretroviral therapy is well-described in the HIV treatment
literature [12,29,30], and findings from this study highlight
that stimulant use may also undermine the clinical and public
health benefits of PrEP.
PrEP implementation has slowly gained traction in recent
years and data from real-world clinical experiences have shown
encouraging results. Recent studies have reported high demand
for PrEP in various clinical settings [31,32] and PrEP implemen-
tation outcomes have seen high overall rates of retention over
time [33-35]. In a study examining retention in care outcomes in
a community-based sexual health clinic in San Francisco, Hojilla
et al. [35] found that stimulant use and unhealthy drinking
behaviours were not significantly associated with PrEP discon-
tinuation. However, an important limitation of the study was its
limited ability to accurately measure PrEP adherence and
recent drug and alcohol use. Because PrEP implementation is in
its early stages [36-38], studies from clinical settings likely
involve a large proportion of highly motivated early adopters
that are not representative of the broader population of MSM
and transgender women. Thus, important questions around
potential barriers to optimal PrEP adherence in this key popula-
tion remain unanswered. Although the field of PrEP research
has advanced considerably since iPrEx OLE, data from this
study remain particularly salient in the context of ongoing dis-
cussions around scale-up and developing strategies to optimize
PrEP delivery with high priority populations.
Our findings support the need to provide PrEP as part of a
comprehensive package that includes an assessment of poten-
tial barriers and interventions to enhance PrEP adherence.
Buchbinder and colleagues’ [39] secondary analysis of data
from the randomized phase of iPrEX estimated that the low-
est number needed to treat (NNT) occurred specifically
among MSM and transgender women who used stimulants
(NNT = 12). Thus, engaging stimulant users in the PrEP con-
tinuum is a high priority. Our work suggests that for PrEP to
achieve its maximum clinical and public health impact, PrEP
delivery models should incorporate efforts to optimize adher-
ence in stimulant-using populations.
Focused work is needed to identify evidence-based inter-
ventions that can mitigate sub-optimal PrEP adherence in
stimulant-using MSM and transgender women, particularly in
the first month of starting the regimen. Expanded efforts with
stimulant users could leverage intensive case management
and follow-up to support PrEP adherence. Integration of evi-
dence-based interventions that directly reduce stimulant use
could also achieve meaningful improvements in PrEP adher-
ence. For example, motivational interviewing and cognitive-
behavioural interventions have demonstrated efficacy in
reducing substance use and sexual risk taking in MSM [40,41].
Clinical research to develop and test interventions to optimize
the prevention effectiveness of PrEP in stimulant users could
achieve more meaningful reductions in HIV incidence.
This study has some limitations. Self-reported responses
may have been prone to recall and social desirability biases,
particularly for sensitive topics like alcohol and other sub-
stance use. We attempted to mitigate misclassification using
urine biomarkers of stimulant use to validate participant
responses, but this may have been incomplete based upon the
limited window of detection for recent stimulant use. We
were also unable to differentiate between frequent and episo-
dic stimulant and alcohol use, which may influence PrEP
adherence in a dose–response manner. Binge drinking was
operationalized as five or more alcoholic drinks in a single day
rather than in one 2-hour sitting [42], which may have overes-
timated the number of individuals classified as binge drinkers
in our study. As sexual risk can fluctuate over time [43], it is
possible that some individuals only took PrEP during periods
of possible exposure (e.g. on-demand dosing). Alternative dos-
ing strategies might account for sub-optimal adherence in
some participants. However, all individuals were counselled on
the importance of daily PrEP use given the limited data avail-
able at the time on intermittent or on-demand PrEP use.
Lastly, we acknowledge that transgender women are a distinct
group of individuals that do not necessarily share the same
psychosocial contexts as MSM. Our study was not sufficiently
powered to detect differences between these groups. Future
studies will need to examine transgender persons separately
to clearly elucidate factors associated with PrEP adherence in
this population.
5 | CONCLUSIONS
In this study, we utilized biomarkers of stimulant use to
reduce misclassification and examined a validated biomarker
of PrEP adherence as the outcome. Our findings demon-
strate that stimulant use is a risk factor for sub-optimal
PrEP adherence in the month following initiation. Identifica-
tion of stimulant use as a risk factor for the impaired pre-
vention effectiveness of PrEP is a crucial first step to
inform the development of comprehensive approaches to
optimize its clinical and public health benefits in high prior-
ity populations.
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